Combination Product GMP Guidance Needs Clarification, Industry Says
Executive Summary
Industry is seeking additional clarification on how and when to apply different sets of manufacturing regulations as the elements of a combination product are joined together
You may also be interested in...
Complete Response, Harmonization, INDs Rank On FDA Regulatory Agenda
Complete response: FDA plans to finalize its proposed rule to replace "approvable"/"not approvable" letters in response to NDAs with complete response letters in October, according to HHS' spring "unified agenda." The rule is intended to fulfill the 1997 FDA Modernization Act requirement to discontinue "approvable"/"not approvable" letters in favor of a standard format. While complete response letters will still identify deficiencies in an application, they are believed less likely to create overreaction by investors. The proposed rule was issued in July 2004 (1"The Pink Sheet" July 26, 2004, p. 10)...
Complete Response, Harmonization, INDs Rank On FDA Regulatory Agenda
Complete response: FDA plans to finalize its proposed rule to replace "approvable"/"not approvable" letters in response to NDAs with complete response letters in October, according to HHS' spring "unified agenda." The rule is intended to fulfill the 1997 FDA Modernization Act requirement to discontinue "approvable"/"not approvable" letters in favor of a standard format. While complete response letters will still identify deficiencies in an application, they are believed less likely to create overreaction by investors. The proposed rule was issued in July 2004 (1"The Pink Sheet" July 26, 2004, p. 10)...
Combo Product Primary Mode Of Action, Dispute Resolution Detailed By FDA
Combination products without regulatory precedent will be assigned to the FDA center with the most expertise in evaluating the products' primary safety and efficacy concerns under a proposed rule